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Total thyroidectomy is increasingly accepted for the
management of patients with benign disease when
both lobes of the thyroid gland are involved (such as
multinodular goiter, thyroiditis, Graves’ disease). This
approach can avoid disease recurrence and eliminate
any subsequent risk of malignant change. Several
authors [1–6] have reported that total thyroidectomy
can be performed safely for treatment of bilateral
benign thyroid disease, and that a low complication
rate can be achieved with a meticulous surgical tech-
nique. However, few studies compare the complica-
tion rates after total thyroidectomy between Graves’
disease and other benign thyroid variants (non-Graves’
disease). The purpose of the present study is to review
the results of our total thyroidectomies for benign
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The purpose of this study was to review the safety of total thyroidectomies for benign thyroid dis-
ease, with special emphasis on the comparison between Graves’ disease and non-Graves’ disease. In
this study, 107 patients who underwent total thyroidectomies for clinically benign thyroid disease
performed by the same surgeon between January 1987 and December 2004 were enrolled; 48 had
Graves’ disease and 59 had non-Graves’ disease. The rates of temporary vs. permanent hypopara-
thyroidism, hematoma requiring surgical intervention, and temporary vs. permanent recurrent
laryngeal nerve palsy (RLNP) after total thyroidectomy for benign thyroid disease were 34.6% vs.
3.7%, 6.5%, and 6.5% vs. 1.85%, respectively. The rates of permanent hypoparathyroidism and tempo-
rary RLNP in the Graves’ disease group were significantly different when compared with the non-
Graves’ disease group (8.3% vs. 0% and 11.5% vs. 2.5%, respectively). However, comparing the rates
of temporary hypoparathyroidism, permanent RLNP, and postoperative hematoma, there was no
statistically significant difference. Compared with total lobectomy, the rates of postoperative hema-
toma increased significantly for total thyroidectomy (6.5% vs. 0.48%). Total thyroidectomy for non-
Graves’ benign thyroid disease may be performed with minimal morbidity as has been advocated by
many authors. For patients with Graves’ disease in this study, however, the complication rates of per-
manent hypoparathyroidism and temporary RLNP were significantly increased. Therefore, we sug-
gest that total thyroidectomy for Graves’ disease should be performed by an experienced surgeon.
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thyroid disease and compare the complication rates
between Graves’ and non-Graves’ disease groups.
PATIENTS AND METHODS
Between January 1987 and December 2004, a total of
601 thyroidectomies were performed by the same sur-
geon at our institution. Among them, 417 had total
lobectomies and 184 had total thyroidectomies. This
study was confined to 107 total thyroidectomies for
clinically benign thyroid disease (48 for Graves’ disease
and 59 for non-Graves’ disease). Patients with Graves’
disease received antithyroid medication to achieve a
euthyroid state before operation. All patients under-
went total thyroidectomy under general anesthesia.
Routine identification of the recurrent laryngeal nerve
(RLN) was performed during all operative procedures.
Autotransplantation of the parathyroid gland was per-
formed routinely when vascular injury was identified
or when the glands were incidentally removed.
Free calcium levels were measured daily preope-
ratively and for at least 4 days postoperatively. All
patients underwent pre- and postoperative laryngo-
scopic examinations of the vocal cords. When recurrent
laryngeal nerve palsy (RLNP) or hypocalcemia was
identified, follow-up was weekly at the beginning,
and every 3–4 weeks thereafter until complete recov-
ery was achieved. RLNP was considered to be per-
manent if it persisted after 6 months. Hypocalcemia
was defined as free calcium level less than 4.0 mg/dL
on at least two consecutive measurements. Temporary
hypoparathyroidism was defined as hypocalcemia
associated with or without symptoms of perioral
paresthesia, tingling of distal extremities or muscle
spasm, and free calcium level that returned to normal
within 6 months. Permanent hypoparathyroidism
was defined as hypocalcemia that persisted for over 6
months and that required active vitamin D and cal-
cium supplementation. The term “hematoma” in this
paper is defined as hematoma requiring surgical
intervention. In this study, the calculation of the
RLNP rate was based on the number of nerves at
risk. Intergroup difference was assessed using the χ2
and Fisher exact tests. A p value of 0.05 or less was
regarded as statistically significant.
RESULTS
The rates of temporary vs. permanent hypopara-
thyroidism, hematoma requiring surgical interven-
tion, and temporary vs. permanent RLNP after total
thyroidectomy for benign thyroid disease were 34.6%
vs. 3.7%, 6.5%, and 6.5% vs. 1.85%, respectively. Table 1
shows the morbidity of total thyroidectomy for 
the Graves’ and non-Graves’ disease groups. Rates 
of temporary/permanent hypoparathyroidism were
37.5%/8.3% for Graves’ disease and 32.2%/0% for
non-Graves’ disease. Rates of temporary/permanent
RLNP were 11.5%/2.0% for Graves’ disease and
2.5%/1.7% for non-Graves’ disease. The rates of post-
operative hematoma were 10.4% for Graves’ disease
and 3.4% for non-Graves’ disease. One of the Graves’
disease patients suffered from thyroid storm with
postoperative hematoma. Compared to the non-
Graves’ disease group, the rates of permanent
hypoparathyroidism and temporary RLNP were 
significantly higher for the Graves’ disease group
(8.3% vs. 0% and 11.5% vs. 2.5%, respectively;
p < 0.05). There were no significant differences in tem-
porary hypoparathyroidism, permanent RLNP, and
Table 1. Morbidity of total thyroidectomy for benign thyroid disease
Chiang et al 2006 (this study) Razack et al 1997 [21] Barakate et al 2002 [22]
Non-GD (n = 59) GD (n = 48) GD (n = 62) GD (n = 119)
n (%) n (%) n (%) n (%)
Temporary hypocalcemia 19 (32.2) 18 (37.5) 22 (35.4) 25 (21)
Permanent hypocalcemia 0 4 (8.3) 1 (1.06) 1 (0.8)
Temporary cord palsy 3 (2.5)* 11 (11.5)* 9 (14.4) 2 (1.7)
Permanent cord palsy 2 (1.7)* 2 (2.0)* 1 (1.6) 1 (0.8)
Hematoma 2 (3.4) 5 (10.4) 0 7 (5.9)
Thyroid storm 0 1 (2.0)
*Palsy rates according to number of nerves at risk. GD = Graves’ disease.
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postoperative hematoma (p > 0.05). The rate of post-
operative hematoma was 6.5% for patients who had
undergone total thyroidectomy, with a significant
increase when compared to the analogous rate for
total lobectomy (6.5% vs. 0.48%; p < 0.05). All patients
who developed hypothyroidism after total thyroidec-
tomy underwent thyroxine replacement. There was
no mortality in this series.
DISCUSSION
Subtotal thyroidectomy has been considered the treat-
ment of choice for benign thyroid disorders, such as
multinodular goiter, thyroiditis, and Graves’ disease.
Lower complication rates after subtotal thyroidectomy
were advocated as compared to total thyroidectomy.
With long follow-up of these cases, however, recur-
rence is often observed after subtotal thyroidectomy,
with rates of 12–45% for nodular goiter [6–11] and
15–27.9% for Graves’ disease [12–15]. Several authors
[16–19] have proposed that reoperation for recurrent
disease carries a very significant risk of damage to the
RLN and parathyroid glands. Therefore, total thyroid-
ectomy has been widely adopted for the management
of patients with benign disease when both lobes of
the thyroid gland are involved. Total lobectomy with
routine RLN identification is our basic procedure for
solitary thyroid nodules [19]. When both lobes of the
thyroid gland are involved, total thyroidectomy is our
preferred option.
The reported complication rates after thyroid sur-
gery are often underestimated because of the lack 
of routine perioperative examination of free calcium
levels and vocal cords to document hypoparathy-
roidism and RLNP. In addition, many reports are 
retrospective and include operations performed by 
a number of surgeons using different surgical tech-
niques over a long period. Thus, in this study, all the
operations were performed by the same surgeon and
perioperative free calcium levels and vocal cords were
routinely examined, with the calculation of the RLNP
rate based on the number of nerves at risk. The calcu-
lation of RLNP rate based on the number of nerves 
at risk seems to be a more logical method that allows
meaningful comparison between different studies
[16,19,20].
The debate over the use of total thyroidectomy 
for the treatment of benign thyroid disease typically
revolves around the higher complication rates, par-
ticularly hypoparathyroidism. In recent literature
[1–4,20–22], the incidence of temporary vs. permanent
hypoparathyroidism after total thyroidectomy for
benign thyroid disease was 12.9–35.4% vs. 0–3.4%
(Table 2). In our series, the incidence of temporary
and permanent hypoparathyroidism was 34.6% and
3.7%, respectively. We found that all cases of perma-
nent hypoparathyroidism were in the Graves’ disease
group. The rates of permanent hypoparathyroidism
in the Graves’ disease group were significantly
higher than that in the non-Graves’ disease group
(8.3% vs. 0%, respectively; p < 0.05). However, the
analogous comparison for temporary hypoparathy-
roidism did not yield a statistically significant differ-
ence (37.5% vs. 32.2%; p > 0.05). Trupka and Sienel
[23] have advocated autotransplantation of at least
one parathyroid gland during total thyroidectomy 
in benign thyroid disease to minimize the risk of 
Table 2. Complication rates of total thyroidectomy for benign thyroid disease
Authors nbt nGD
Hypoparathyroidism, n (%) RLNP, n (%) Hematoma,
Temporary Permanent Temporary Permanent n (%)
Razack et al 1997 [21] 62 62 22 (35.4) 1 (1.06) 9 (14.4) 1 (1.6) —
Liu et al 1998 [2] 106 24 28 (26.4) 0 (0) 3 (2.8) 2 (1.9) 1 (0.9)
Mishra et al 2001 [1] 127 37 41 (32.3) 2 (1.6) 6 (4.7) 1 (0.8) 1 (0.8)
Barakate et al 2002 [22] 119 119 25 (21.0) 1 (0.8) 2 (1.7) 1 (0.8) 7 (5.9)
Bellantone et al 2002 [20] 526 65 41 (7.8) 18 (3.4) 15 (1.4)* 4 (0.4) 8 (1.5)
Friguglietti et al 2003 [3] 782 53 101 (12.9) 10 (1.27) 17 (2.17) 3 (0.38) 2 (0.25)
Bron & O’Brien 2004 [4] 834 47 120 (14.4) 20 (2.4) 19 (2.3) 9 (1.1) 15 (1.8)
Chiang et al 2006 (this study) 107 48 37 (34.6) 4 (3.7) 14 (6.5)* 4 (1.85)* 7 (6.5)
*Palsy rates according to number of nerves at risk. nbt = total number of patients with benign thyroid disease; nGD = number of Graves’
disease patients; n = number of patients.
permanent hypoparathyroidism. In our study, four
Graves’ disease patients with permanent hypoparathy-
roidism underwent at least one parathyroid auto-
transplantation (two had one, one had two, and the
remaining one had three glands implanted). Although
not statistically validated, this result suggests that
parathyroid autotransplantation cannot guarantee
avoidance of permanent hypoparathyroidism. In this
study, the reason for why permanent hypoparathyroi-
dism was more prevalent after total thyroidectomy for
Graves’ disease is unclear. Among the four Graves’
disease patients with permanent hypoparathyroidism,
we found that two patients (one patient had three
glands, and the other had two glands implanted) suf-
fered postoperative hematoma, and the other two
patients who had one gland implanted underwent
parathyroid autotransplantation at the end of the
operation. This may indicate that postoperative hema-
toma and delayed autotransplantation might be the
culprits of graft failure. We had already modified our
surgical technique of parathyroid autotransplantation
by: (1) transplanting the devascularized gland imme-
diately; (2) preparing the muscle pocket carefully to
prevent hematoma; (3) mincing the gland into pieces
as small as possible; (4) transplanting the glands into
bilateral sternocleidomastoid muscles if more than one
gland needed autotransplantation.
The reported incidence of temporary RLNP after
total thyroidectomy for benign thyroid disease varies
from 1.7% to 14.4%, and the incidence of permanent
RLNP ranges from 0.38% to 1.9% (Table 2). In our
study, the incidences of temporary and permanent
RLNP were 6.5% and 1.85% of the nerves at risk,
respectively. The rate of temporary RLNP in the
Graves’ disease group was significantly higher than
that in the non-Graves’ disease group (11.5% vs. 2.5%;
p < 0.05); however, as to the rate of permanent RLNP
(2.0% vs. 1.7%; p>0.05), there was no significant differ-
ence. Several authors [21,24–26] have also reported
higher temporary RLNP rates (8–14.4%) after surgery
for Graves’ disease. Furthermore, we found that
stretching of the nerve occurred more frequently dur-
ing dissection of the RLN from a large thyroid mass
with increased vascularity, and it seems to be reason-
able to suggest that this stretching phenomenon is
the reason for the higher rate of temporary RLNP in
these patients.
All wounds were closed with suction drainage rou-
tinely. One drain tube was used for total lobectomy
and two for total thyroidectomy. In our study, all
postoperative hematomas occurred within 24 hours
of the operation, and it was unusual in patients 
after unilateral total lobectomy. Rates of postopera-
tive hematoma were 0.48% (2/417) after total lobec-
tomy and 6.5% (7/107) after total thyroidectomy.
Postoperative hematoma appeared to be more com-
mon in the Graves’ disease group; however, no sig-
nificant difference between the two groups was
demonstrated (10.4% vs. 3.4%; p > 0.05). We found
that postoperative hematoma still occurred after thy-
roidectomy, even though meticulous hemostasis had
been performed for every patient. For patients with
Graves’ disease awaiting operation, oral potassium
iodine (Lugol) may be considered before thyroidec-
tomy to minimize postoperative hematoma. Thyroid
storm has become a rare problem with the advent of
antithyroid drugs. We operated only on patients
whose thyrotoxic state had been brought under con-
trol. However, thyroid storm still occurs infrequently
with surgical manipulation of the thyroid gland.
Thyroid storm occurred in one of our Graves’ disease
patients when the operation had just been completed.
Hematoma, high fever, and tachycardia occurred
suddenly before the patient was sent to the recovery
room. Fortunately, this patient recovered unevent-
fully after emergent management.
Three strategies are now available for the treatment
of Graves’ disease: antithyroid drugs, surgery, and
radioactive iodine. None of them has been shown to
be ideal or superior to the other two. Physicians in
different countries use varying approaches to provide
optimal treatment for Graves’ disease. Antithyroid
drugs are our first line of therapy for this disease.
Our indications for surgery in Graves’ disease were:
(1) large goiter; (2) worsening ophthalmopathy; (3)
suspected concomitant thyroid malignancy; (4) severe
side effects of antithyroid drug treatment. Total 
thyroidectomy is our preferred option for Graves’ 
disease because it has the advantages of immediate
cure of any hyperthyroidism, avoidance of recur-
rence, and diminution of cancer risk. The reported
prevalence for coexistent thyroid cancer ranges from
2.1% to 5% of Graves’ disease patients [21,22,
27]. In this study, out of the 48 Graves’ disease cases, 
six (12.5%) were associated with occult thyroid 
cancer.
In conclusion, this study showed that total thy-
roidectomy may be performed with minimal morbidity
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in non-Graves’ disease cases with benign thyroid 
disease, as claimed by many surgeons. But the risks
of permanent hypoparathyroidism and temporary
RLNP increased significantly in Graves’ disease
patients after total thyroidectomy. The risk of post-
operative hematoma was also higher in patients with
Graves’ disease, but this difference did not reach 
statistical significance. Therefore, the operation in
Graves’ disease patients requires a more skilled tech-
nique because of the high vascularity of the thyroid
gland. Our main point is that patients must par-
ticipate fully in the choice of treatment for Graves’
disease and be fully informed with respect to the
advantages and disadvantages of each form of ther-
apy [21]. It is recommended that total thyroidectomy
for Graves’ disease be performed by an experienced
surgeon.
REFERENCES
1. Mishra A, Agarwal A, Agarwal G, et al. Total thy-
roidectomy for benign thyroid disorders in an endemic
region. World J Surg 2001;25:307–10.
2. Liu Q, Djuricin G, Prinz RA. Total thyroidectomy for
benign thyroid disease. Surgery 1998;123:2–7.
3. Friguglietti CU, Lin CS, Kulcsar MA. Total thyroidec-
tomy for benign thyroid disease. Laryngoscope 2003;
113:1820–6.
4. Bron LP, O’Brien CJ. Total thyroidectomy for clinically
benign disease of the thyroid gland. Br J Surg 2004;
91:569–74.
5. Colak T, Akca T, Kanik A, et al. Total versus subtotal
thyroidectomy for the management of benign multi-
nodular goiter in an endemic region. ANZ J Surg 2004;
74:974–8.
6. Reeve TS, Delbridge L, Cohen A, et al. Total thyroidec-
tomy. The preferred option for multinodular goiter.
Ann Surg 1987;206:782–6.
7. Torre G, Barreca A, Borgonovo G, et al. Goiter recur-
rence in patients submitted to thyroid-stimulating hor-
mone suppression: possible role of insulin-like growth
factors and insulin-like growth factor-binding proteins.
Surgery 2000;127:99–103.
8. Jenny H, Block MA, Horn RC, et al. Recurrence follow-
ing surgery for benign thyroid nodules. Arch Surg
1966;92:525–9.
9. Wadstrom C, Zedenius J, Guinea A, et al. Multinodular
goitre presenting as a clinical single nodule: how effec-
tive is hemithyroidectomy? Aust N Z J Surg 1999;69:
34–6.
10. Rojdmark J, Jarhult J. High long term recurrence rate
after subtotal thyroidectomy for nodular goitre. Eur J
Surg 1995;161:725–7.
11. Bellantone R, Lombardi CP, Boscherini M, et al. Pre-
dictive factors for recurrence after thyroid lobectomy
for unilateral non-toxic goiter in an endemic area: results
of a multivariate analysis. Surgery 2004;136:1247–51.
12. Davenport M, Talbot CH. Thyroidectomy for Graves’
disease: is hypothyroidism inevitable? Ann R Coll Surg
Engl 1989;71:87–91.
13. Cusick EL, Krukowski ZH, Matheson NA. Outcome 
of surgery for Graves’ disease re-examined. Br J Surg
1987;74:780–3.
14. Ozoux JP, de Calan L, Portier G, et al. Surgical treat-
ment of Graves’ disease. Am J Surg 1988;156:177–81.
15. Kasuga Y, Sugenoya A, Kobayashi S, et al. Clinical
evaluation of the response to surgical treatment of
Graves’ disease. Surg Gynecol Obstet 1990;170:327–30.
16. Martensson H, Terins J. Recurrent laryngeal nerve
palsy in thyroid gland surgery related to operations
and nerves at risk. Arch Surg 1985;120:475–7.
17. Beahrs OH, Vandertoll DJ. Complications of secondary
thyroidectomy. Surg Gynecol Obstet 1963;117:535–9.
18. Jatzko GR, Lisborg PH, Muller MG, et al. Recurrent
nerve palsy after thyroid operations—principal nerve
identification and a literature review. Surgery 1994;115:
139–44.
19. Chiang FY, Wang LF, Huang YF, et al. Recurrent laryn-
geal nerve palsy after thyroidectomy with routine identi-
fication of the recurrent laryngeal nerve. Surgery 2005;
137:342–7.
20. Bellantone R, Lombardi CP, Bossola M, et al. Total thy-
roidectomy for management of benign thyroid disease:
review of 526 cases. World J Surg 2002;26:1468–71.
21. Razack MS, Lore JM Jr, Lippes HA, et al. Total thyroidec-
tomy for Graves’ disease. Head Neck 1997;19:378–83.
22. Barakate MS, Agarwal G, Reeve TS, et al. Total thyroidec-
tomy is now the preferred option for the surgical man-
agement of Graves’ disease. ANZ J Surg 2002;72:321–4.
23. Trupka A, Sienel W. Autotransplantation of at least one
parathyroid gland during thyroidectomy in benign
thyroid disease minimizes the risk of permanent
hypoparathyroidism. Zentralbl Chir 2002;127:439–42.
24. Agarwal A, Mishra SK. Role of surgery in the manage-
ment of Graves’ disease. J Indian Med Assoc 2001;99:
252, 54–6.
25. Thomusch O, Machens A, Sekulla C, et al. Multivariate
analysis of risk factors for postoperative complications
in benign goiter surgery: prospective multicenter study
in Germany. World J Surg 2000;24:1335–41.
26. Wagner HE, Seiler C. Recurrent laryngeal nerve palsy
after thyroid gland surgery. Br J Surg 1994;81:226–8.
27. Palit TK, Miller CC III, Miltenburg DM. The efficacy of
thyroidectomy for Graves’ disease: a meta-analysis. 
J Surg Res 2000;90:161–5.
























 !"!= = != = !
O




 ! "#$%&'()*+,-./01 )*+2345678 97:;
 !=dê~îÉë= !=dê~îÉë= !"#$%&'()*=NVUT==N=
=OMMQ==NO= !"#$%&'()*+,-.&'(/0%*12=NMT=
 !"#$%&'()'*+,-.= QU== dê~îÉë= RV= 
dê~îÉë= !"#$%&'=L= !"#$%&'()*+ =L= !"
 !"#$%&'=PQKSBLPKTB==SKRBLNKURB !"#$%&'()*+
 !"#$%&'()*+),-=dê~îÉë= !"#=dê~îÉë= !
 !"#$%&'()*+,-./01234567,89:;<=>?@A
 !"#$%&'()*+,-./0123456789:0;<=>?@
dê~îÉë= !"#$%&'()*=dê~îÉë= !"#$% &'()
 !"#$%&'()*+,-./0123456789 :;<=>
dê~îÉë= !"#$%&'
 dê~îÉë= !"# $%&'() *+, *+,-./
E !=OMMSXOOWRRQVF
